Clinical Trial Update: Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating low-dose tamoxifen citrate to reduce breast cancer risk in radiation-induced cancer survivors. Results were posted in January 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Tamoxifen citrate (tamoxifen citrate)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2020-01-27